TSHZ2 and ductal breast carcinoma in situ: The present findings demonstrate that miR‐217 inhibits the malignant characteristics of DCIS cells by regulating the DNMT1/TSHZ2/Hedgehog‐GLI signaling axis, highlighting its potential as a novel targeted therapy for DCIS.